Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Compared with traditional drug therapy, nanomedicines exhibit intriguing biological features
to increase therapeutic efficiency, reduce toxicity and achieve targeting delivery. This review …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

Abstract The claudin18. 2 (CLDN18. 2) protein, an isoform of claudin18, a member of the
tight junction protein family, is a highly selective biomarker with limited expression in normal …

Antibody-drug conjugates (ADCs) are a class of innovative biopharmaceutical drugs, which,
via their antibody (mAb) component, deliver and release their potent warhead (aka. payload) …

When gastrointestinal stromal tumour (GIST), the most common form of sarcoma, was first
recognized as a distinct pathological entity in the 1990s, patients with advanced-stage …

The potential roles of breast cancer stem cells (BCSCs) in tumor initiation and recurrence
have been recognized for many decades. Due to their strong capacity for self-renewal and …

Combining existing drug therapy is essential in developing new therapeutic agents in
disease prevention and treatment. In preclinical investigations, combined effect of certain …

Simple Summary A proportion of breast tumors bear the oncogenic transmembrane tyrosine
kinase protein HER2. Even though therapies that target HER2 have changed the prognosis …

Despite significant advances in the treatment of cervical, ovarian, and uterine cancers with
the approvals of checkpoint and PARP inhibitors into standard treatment, patients with …